辅舒酮吸入配合小青龙汤对哮喘患者肺功能和血清白细胞介素-16水平的影响

Effect of Fluticasone Inhalation Combined with Xiaoqinglong Decoction on Pulmonary Function and Serum In-terleukin-16 Level in Asthma Patiens

目的:观察辅舒酮吸入配合小青龙汤对哮喘患者肺功能和血清IL-16的影响。方法:选择中、重度哮喘发作期患者54例,随机分为3组。治疗组:辅舒酮吸入配合小青龙汤口服;辅舒酮组:单纯辅舒酮吸入;小青龙汤组:单纯口服小青龙汤。治疗前和治疗4周后测定肺通气功能FEV_1和呼吸阻抗R_5,用酶联免疫吸附法测定血清白细胞介素-16(IL-16)的水平。另选10例健康志愿者作为对照组。结果:治疗后3组患者肺通气功能FEV_1均显著增加、呼吸阻抗R_5均显著减少(P<0.05或P<0.01),但以治疗组改善最为明显(P<0.01)。治疗前3组IL-16水平均显著高于健康对照组(P<0.01),治疗后各组IL-16水平明显下降(P<0.05或P<0.01),以治疗组下降最为明显(P<0.01)。血清IL-16含量分别与FEV_1、R_5值呈负相关和正相关(r_1=-0.67,r_2=0.71,P均<0.01)。结论:辅舒酮吸入配合口服小青龙汤对哮喘患者肺功能改善和抑制血清IL-16的作用,明显优于单纯吸入辅舒酮或单纯口服小青龙汤,可成为中、重度哮喘的重要治疗手段。

Objective: To observe the effect of Fluticasone inhalation combined with Xiaoqinglong decoction (XQLD) on pulmonary function and serum interleukin-16 (IL-16) level in asthma patients. Methods: Fifty-four mild or severe asthma patients were selected and randomly divided into three groups. The treated group was treated with Fluticasone inhalation combined with XQLD, Fluticasone group treated with Fluticasone inhalation, and XQLD group treated with XQLD respectively. Meanwhile ten healthy volunteers were selected as healthy control group. The conventional pulmonary function FEVj and respiratory impedance R5 were measured before and after 4 weeks treatment. The IL-16 levels were determined by using ELISA. Results: FEV1 were obviously increased and R5 decreased in the three groups after treatment (P<0.05 or P<0.01), but the improvement was more significant in the treated group (P<0.01). Before treatment, serum levels of IL-16 in all the three groups were significantly higher than those in the healthy control group (P<0.01) and lowered after treatment respectively, the treated group was significantly lower than those of the other two groups (P<0.05 or P<0.01). The serum level of IL-16 was negatively correlated with FEVi and positively with R5( r1=- 0.67, r2 = 0.71, P< 0.01). Conclusion:The effects of Fluticasone inhalation combined with XQLD on pulmonary function and serum IL-16 levels were superior to those of Fluticasone inhalation and XQLD alone in asthma patients. So it could become an important therapeutical method in treating mild and severe asthma patients.